Search

ARCoV

SARS-CoV-2 mRNA vaccine (ARCoV) is a novel mRNA coronavirus vaccine that consists of a lipid nanoparticle-encapsulated mRNA encoding the receptor binding domain of SARS-CoV-2[A220048]. … Preclinical studies in mice and non-human primates has shown that intramuscular administration of ARCoV elicited a Th1-biased cellular response and robust antibodies against SARS-CoV-2[A220048].

PlasmaCord

[L27581] It is developed by Cellpraxis and is currently being investigated against severe acute respiratory syndrome (SARS).

Quinine

Quinine (GLS-1200) was also investigated in clinical trials for its efficacy in preventing SARS-CoV-2 infection (NCT04408183, terminated) and is planned to be evaluated for preventing sinusitis after endoscopic

Lopinavir

[A191757] Lopinavir was previously under investigation in combination with ritonavir for the treatment of COVID-19 caused by SARS-CoV-2.[L12012]

Vecabrutinib

Vecabrutinib is under investigation in clinical trial NCT03037645 (Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers).

Meplazumab

Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.

Virus Specific T-Cell

Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. These products are generated from virus-naive or virus-experienced autologous or allogenic sources. Antigens identified as an immune targe...

Umifenovir

[A191475] Umifenovir is currently being investigated as a potential treatment and prophylactic agent for COVID-19 caused by SARS-CoV2 infections in combination with both currently available and investigational

Fibrinogen human

Fibrinogen concentrate (human) is a hematological agent. It works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting. It is a soluble plasma glycoprotein with a molecular weight of about 3...

Didecyldimethylammonium